Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2023-06-21 Regulatory Filings
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL BIOSCIENCES: Approval for its patent to be granted on NFL-101 in Europe and approval of the clinical development plan for NFL-101 by the EMA
Regulatory Filings Classification · 95% confidence The document announces two key developments for NFL Biosciences: the approval for its patent (NFL-101) to be granted in Europe and the approval of its clinical development plan for NFL-101 by the European Medicines Agency (EMA). This type of announcement, detailing regulatory milestones, clinical progress, and intellectual property updates, is characteristic of general corporate news releases intended for investors and the public. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it is a specific announcement about regulatory/clinical progress and patent protection, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate event announcement, or potentially 'Capital/Financing Update' (CAP) if the focus was on funding, but here the focus is on IP and clinical progress. Given the options, RNS serves as the best fit for a general, material corporate announcement that doesn't fit a more specific category like ER or 10-K, although it contains elements related to drug development which might sometimes fall under LTR if it were a legal dispute, but here it is positive regulatory news. Since there is no specific category for 'Clinical/IP Update', RNS is the most appropriate catch-all for material news.
2023-06-21 English
NFL Biosciences : Modalités de mise à disposition et consultation des documents préparatoires à l'Assemblée Générale Mixte du 27 juin 2023
AGM Information Classification · 98% confidence The document explicitly mentions 'ASSEMBLÉE GÉNÉRALE MIXTE DU 27 JUIN 2023' (Combined General Meeting of June 27, 2023) and details the modalities for making preparatory documents available to shareholders. This content directly relates to the Annual General Meeting (AGM). Although it mentions the publication of the notice of meeting, the core subject is the upcoming AGM and the associated documentation/procedures, making 'AGM Information' (AGM-R) the most appropriate classification over a general 'Report Publication Announcement' (RPA) or 'Proxy Solicitation' (PSI), as it focuses on the event itself and document availability related to it.
2023-06-09 French
NFL Biosciences : Finalisation des recrutements de l’étude PRECESTO
Regulatory Filings Classification · 95% confidence The document announces the finalization of recruitment for the PRECESTO clinical study concerning the drug NFL-101 for smoking cessation. It details the study's purpose, timeline (recruitment finished May 5, 2023, first results Q3 2023), funding sources, and quotes management. This type of announcement, focusing on clinical trial progress and operational updates rather than comprehensive financial results (10-K, IR) or formal regulatory filings, fits best under a general corporate update or announcement. Since it is not a formal Earnings Release (ER), a Call Transcript (CT), or a specific financial report (IR, 10-K), and it relates to ongoing business operations and development milestones, it is most appropriately classified as a Regulatory Filing (RNS) as a general corporate announcement, or potentially an Investor Presentation (IP) if it were structured as a deck, but given the format, RNS serves as the best fit for a press release detailing operational progress that isn't explicitly covered by other codes like DIV, CAP, or ER. The length (under 5000 chars) suggests it is a brief announcement, not a full report.
2023-05-09 French
NFL Biosciences: Recruitment completed for the PRECESTO study
Regulatory Filings Classification · 99% confidence The document announces the completion of recruitment for the PRECESTO clinical trial, detailing the study's purpose (smoking cessation treatment complementarity), the number of volunteers, the timeline for initial results (Q3 2023), and funding sources. This is a specific operational update regarding clinical development and progress, not a formal financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It is an announcement about a specific business/development milestone. Since there is no specific category for 'Clinical Trial Update' or 'Operational Milestone', and it is not a general regulatory filing (RNS) or a presentation (IP), it best fits under 'Regulatory Filings' (RNS) as a general corporate announcement that doesn't fit the other specific categories, or potentially 'LTR' if the trial itself was regulatory-driven, but RNS is the safer general announcement fallback for non-financial/non-governance operational news.
2023-05-09 English
NFL Biosciences : Mise à disposition du Rapport Annuel au 31/12/2022
Audit Report / Information Classification · 98% confidence The document is a short announcement dated April 28, 2023, stating that NFL Biosciences has made its 'Rapport Annuel au 31/12/2022' (Annual Report for the year ended 12/31/2022) available to the public and filed it with the AMF (Autorité des Marchés Financiers). Applying the 'MENU VS MEAL' rule: Since the document is short (2031 characters) and its primary function is to announce the publication and availability of the Annual Report, it should be classified as a Report Publication Announcement (RPA), rather than the Annual Report (10-K) itself. It explicitly states 'Mise à disposition du Rapport Annuel' (Making available of the Annual Report) and provides a link to where it can be consulted. FY 2022
2023-04-28 French
NFL Biosciences : Activités & Résultats annuels 2022
Annual Report Classification · 95% confidence The document is a comprehensive report titled 'Activités & Résultats annuels 2022' for NFL Biosciences. It provides detailed financial statements (balance sheet, income statement), management commentary on business activities, clinical trial progress, and governance changes. Although it mentions that the full annual report will be published later, this document itself contains the substantive financial data and analysis for the fiscal year 2022, qualifying it as an Annual Report (10-K equivalent for this jurisdiction). FY 2022
2023-04-25 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.